Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability
暂无分享,去创建一个
Joel Greshock | Nancy Liu-Sullivan | Richard Wooster | B. Weber | S. Powers | J. Greshock | K. Bachman | R. Wooster | J. Jackson | A. Gilmartin | Xiping Zhang | C. Moy | W. Halsey | S. Laquerre | Scott Powers | Y. Degenhardt | Junping Jing | Jeffrey Jackson | Barbara Weber | M. Richter | Maureen R. Bleam | Ashley M. Hughes | Nancy Liu-Sullivan | Yan Degenhardt | Sylvie Laquerre | Xiping Zhang | Aidan G Gilmartin | Junping Jing | Mark Richter | Maureen Bleam | Wendy Halsey | Ashley Hughes | Christopher Moy | Kurtis Bachman
[1] H. Watari,et al. Functional analysis of p53 gene and the prognostic impact of dominant‐negative p53 mutation in endometrial cancer , 2005, International journal of cancer.
[2] G. S. Johnson,et al. An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.
[3] H. Lane,et al. Cell-cycle control: POLO-like kinases join the outer circle. , 1997, Trends in cell biology.
[4] Z. Szallasi,et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.
[5] M. Loda,et al. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. , 2006, Cancer research.
[6] R. Wolthuis,et al. Polo-like Kinase-1 Is Required for Bipolar Spindle Formation but Is Dispensable for Anaphase Promoting Complex/Cdc20 Activation and Initiation of Cytokinesis* , 2004, Journal of Biological Chemistry.
[7] J. Jackson,et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. , 2009, Cancer research.
[8] Jan Ellenberg,et al. Roles of Polo-like Kinase 1 in the Assembly of Functional Mitotic Spindles , 2004, Current Biology.
[9] T. Mitsudomi,et al. Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. , 2001, The American journal of pathology.
[10] J. Weinstein,et al. Karyotypic complexity of the NCI-60 drug-screening panel. , 2003, Cancer research.
[11] M. Carroll,et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.
[12] M. Tsao,et al. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. , 2004, Molecular cancer therapeutics.
[13] G. Wahl,et al. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. , 1997, Cancer research.
[14] W. Dai,et al. Polo-like kinases in cell cycle checkpoint control. , 2003, Frontiers in bioscience : a journal and virtual library.
[15] M. Ellis,et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Takao Takahashi,et al. Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers , 2003, Cancer science.
[17] Cheng Li,et al. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data , 2004, Bioinform..
[18] K. Kinzler,et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 , 2009, Proceedings of the National Academy of Sciences.
[19] Michael J. Emanuele,et al. A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.
[20] K. Hagiwara,et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp , 2006, British Journal of Cancer.
[21] Michael B Yaffe,et al. Structure and function of Polo-like kinases , 2005, Oncogene.
[22] C. von Ilberg,et al. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. , 1999, Cancer research.
[23] Jonathan Scott Friedlaender,et al. A Human Genome Diversity Cell Line Panel , 2002, Science.
[24] T. Jacks,et al. Characterization of the p53-Dependent Postmitotic Checkpoint following Spindle Disruption , 1998, Molecular and Cellular Biology.
[25] N. Takai,et al. Polo-like kinase (PLK) expression in endometrial carcinoma. , 2001, Cancer letters.
[26] Ajay N. Jain,et al. Breast tumor copy number aberration phenotypes and genomic instability , 2006, BMC Cancer.
[27] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[28] M. Wigler,et al. Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.
[29] M. Lei,et al. Normal Cells, but Not Cancer Cells, Survive Severe Plk1 Depletion , 2006, Molecular and Cellular Biology.
[30] N. Takai,et al. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. , 2001, Cancer letters.
[31] P. Meraldi,et al. Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation. , 2003, Developmental cell.
[32] R. Grobholz,et al. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. , 2000, Pathology, research and practice.
[33] A. Martin,et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines , 2007, Cell proliferation.
[34] Ran Guan,et al. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. , 2005, Cancer research.
[35] Jun Yoshimatsu,et al. Polo-like kinases (Plks) and cancer , 2005, Oncogene.
[36] A. Iafrate,et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling , 2007, Proceedings of the National Academy of Sciences.
[37] M. Santoro,et al. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. , 2009, Cancer research.
[38] G. Wahl,et al. p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. , 1998, Cancer research.
[39] E. Nigg. Polo-like kinases: positive regulators of cell division from start to finish. , 1998, Current opinion in cell biology.
[40] J. Marine,et al. Mdm2-mediated ubiquitylation: p53 and beyond , 2010, Cell Death and Differentiation.
[41] L. Chin,et al. A comparison of DNA copy number profiling platforms. , 2008, Cancer research.
[42] M. Bittner,et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. , 2007, Cancer research.
[43] T. Soussi,et al. p53 mutation heterogeneity in cancer. , 2005, Biochemical and biophysical research communications.
[44] H. Ackermann,et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer , 1997, Oncogene.